Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Decoy-20’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Decoy-20 is under development for the treatment of solid tumors including colorectal cancer, pancreatic cancer, bladder carcinoma, breast cancer, cervical cancer, non-Hodgkin lymphoma and hepatocellular carcinoma-associated HBV infection and human immunodeficiency virus (HIV) infection. It comprises of a single strain of killed and intact, non-pathogenic gram bacteria with reduced LPS-endotoxin activity. it is administered through intravenous route.
Indaptus Therapeutics overview
Indaptus Therapeutics (Indaptus) operates as a clinical stage biopharmaceutical company. Indaptus is headquareterd in New York City, New York, the US.
For a complete picture of Decoy-20’s drug-specific PTSR and LoA scores, buy the report here.